Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion
Open Access
- 16 May 2023
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 11 (5) , 1452
Abstract
Atrial fibrillation (AF) is associated with atrial remodeling, cardiac dysfunction, and poor clinical outcomes. External direct current electrical cardioversion is a well-developed urgent treatment strategy for patients presenting with recent-onset AF. However, there is a lack of accurate predictive serum biomarkers to identify the risks of AF relapse after electrical cardioversion. We reviewed the currently available data and interpreted the findings of several studies revealing biomarkers for crucial elements in the pathogenesis of AF and affecting cardiac remodeling, fibrosis, inflammation, endothelial dysfunction, oxidative stress, adipose tissue dysfunction, myopathy, and mitochondrial dysfunction. Although there is ample strong evidence that elevated levels of numerous biomarkers (such as natriuretic peptides, C-reactive protein, galectin-3, soluble suppressor tumorigenicity-2, fibroblast growth factor-23, turn-over collagen biomarkers, growth differential factor-15) are associated with AF occurrence, the data obtained in clinical studies seem to be controversial in terms of their predictive ability for post-cardioversion outcomes. Novel circulating biomarkers are needed to elucidate the modality of this approach compared with conventional predictive tools. Conclusions: Biomarker-based strategies for predicting events after AF treatment require extensive investigation in the future, especially in the presence of different gender and variable comorbidity profiles. Perhaps, a multiple biomarker approach exerts more utilization for patients with different forms of AF than single biomarker use.Keywords
This publication has 223 references indexed in Scilit:
- Plasma Asymmetric Dimethylarginine and Adverse Events in Patients with Atrial Fibrillation Referred for Coronary AngiogramPLOS ONE, 2013
- Conduction Remodeling in Human End-Stage Nonischemic Left Ventricular CardiomyopathyCirculation, 2012
- Plasma resistin, adiponectin, and risk of incident atrial fibrillation: The Framingham Offspring StudyAmerican Heart Journal, 2012
- Is Discharge to Home After Emergency Department Cardioversion Safe for the Treatment of Recent-Onset Atrial Fibrillation?Annals of Emergency Medicine, 2011
- Electrophysiological remodeling in heart failureJournal of Molecular and Cellular Cardiology, 2010
- Relations of Biomarkers of Distinct Pathophysiological Pathways and Atrial Fibrillation Incidence in the CommunityCirculation, 2010
- Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversionInternational Journal of Cardiology, 2009
- Long‐Term Prognostic Value of Baseline C‐Reactive Protein in Predicting Recurrence of Atrial Fibrillation after Electrical CardioversionPacing and Clinical Electrophysiology, 2008
- Modelling cardiac fibroblasts: interactions with myocytes and their impact on impulse propagationEP Europace, 2007
- High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversionInternational Journal of Cardiology, 2006